摘要
目的：评估生长抑素（施他宁，ｓｔｉｌａｍｉｎ）对急性水肿型胰腺炎（ＡＥＰ）的治疗价值及应用指征。方法：用回顾性分析方法，将１６３例ＡＥＰ按年龄及有否加用生长抑素分为４组。按下列指标评估：腹痛消失时间、血淀粉酶复常时间、转为急性重症胰腺炎（ＡＮＰ）发生率、手术率、病死率。结果：大于５５岁的两组，腹痛消失时间生长抑素治疗组（治疗组）为（２．５±１．７）天；无生长抑素组（对照组）为（４．９±２．２）天，Ｐ＜０．０５；血淀粉酶复常时间治疗组为（３．２±１．８）天；对照组为（４．８±２．８）天，Ｐ＜０．０５；转为ＡＮＰ的发生率，治疗组为８％（３／４０）；对照组为２３％（７／３１），Ｐ＞０．０５；转手术率，治疗组为５％（２／４０）；对照组为１６％（５／３１），Ｐ＞０．０５。小于或等于５５岁的两组，腹痛消失时间和血淀粉酶复常时间均无统计学差别。结论：ＡＥＰ高龄患者早期应用生长抑素治疗，能缩短病程，改善预后。
Objective: To assess the value and indications of somatostatin(stilamin) in the treatment of acute edematous pancreatitis(AEP).Methods: Abdominal pain duration; raised serum amylase period; surgical intervention rate, mortality rate and occurrence rate of acute necrosis pancreatitis (ANP) were investigated in 163 cases with AEP. Results: In the old patients whose ages>55, abdominal pain duration was (2.5±1.7) days in treatment group with somatostatin and (4 9±2 2) days in control group respectively( P <0 05). Raised serum amylase period was (3 2±1 8) days in treatment group with somatostatin and (4 8±2 8)days period in control group respectively( P <0 05). Occurrence rate of ANP was 8 %(3 out of 40 cases) in treatment group with somatostatin while 23 %(7 out of 31 cases) in control group ( P >0 05), Surgical intervention rate was 5%(2 out of 40 cases) in treatment group with somatostatin while 16%(5 out of 31 cases) in control group ( P >0 05). In the young patients( ages≤55), no significant differences were found in both treatment group with somatostatin and control group . Conclusion: somatostatin in the old patients with AEP can shorten the course of the disease and improve prognosis.
出处
《新医学》
1999年第5期265-266,共2页
Journal of New Medicine
